

MAY 14 2002

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031RECEIVED
MAY 20 2002
TECH CENTER 1600/2900

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/729,478
	Filing Date	December 4, 2000
	First Named Inventor	Peter J. Kushner
	Group Art Unit	1646
	Examiner Name	E. Kemmerer
	Attorney Docket Number	407T-896330US
	Date Submitted	

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
OK	1	5,071,773	—	Evans	12-10-1991	—

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
OK	2	WO	95/06754		The Regents of the University of California	09-03-1995	—	
↓	3	EP	0629697 A2		Eli Lilly and Co.	12-21-1994	—	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
OK	4	Andersson et al., (1992) "Carcinogenic Effects of Adjuvant Tamoxifen Treatment and Radiotherapy for Early Breast Cancer" <i>Acta Oncologica</i> 31(2), 259-263.	
	5	Angel and Karin, (1991) "The Role of Jun, Fos and the AP-1 complex in cell-production and transformation." <i>Biochimica et Biophysica Acta</i> . 1072:129-157.	
	6	Anzai et al. (1989) "Stimulatory Effects of 4-Hydroxytamoxifen on Proliferation of Human Endometrial Adenocarcinoma Cells." <i>Cancer Res.</i> 49:2362-2365	
	7	Berry, et al., (1990) "Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen." <i>EMBO J.</i> 9(9), 2811-2818.	
	8	Bracke, et al., (1991) "Retinoic acid modulates both invasion and plasma membrane ruffling of MCF-7 human mammary carcinoma cells in vitro." <i>Br. J. Cancer</i> 63:867-872.	
	9	Dauvois, et al (1992) "Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover." <i>Proc. Natl. Acad. Sci. USA</i> 89:4037-4041.	
	10	Davis et al (1993) "Medical Hypothesis: Xenoestrogens as Preventable Causes of Breast Cancer." <i>Environmental Health Perspectives</i> , 101(5):372-377.	

Angelo et al. (1991) "Effect of tamoxifen on the growth of human breast cancer cells in vitro and in vivo." *Journal of Clinical Investigation* 87:1000-1005.
 inhibits oestrogen receptor activity in human breast cancer derived cells. *EMBO J.* 10(8):2237-2245.

	12	Dubik, et al. (1992) "Mechanism of estrogen activation of c-myc oncogene expression." <i>Oncogene</i> , 7:1587-1594.	
--	----	--	--

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/729,478
	Filing Date	December 4, 2000
	First Named Inventor	Peter J. Kushner
	Group Art Unit	1646
	Examiner Name	E. Kemmerer
	Attorney Docket Number	407T-896330US
	Date Submitted	

Cell	13	Fawell et al. (1990) "Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization." <i>Proc. Natl. Acad. Sci.</i> vol. 87, pp. 6883-6887.
	14	Gaub, et al., (1990) "Activation of the Ovalbumin Gene by the Estrogen Receptor Involves the Fos-Jun Complex." <i>Cell</i> 63:1267-1276.
	15	Horovitz, (1992) "Cellular Heterogeneity and Mutant Oestrogen Receptors in Hormone Resistant Breast Cancer." <i>Cancer Surveys</i> 14:41-54 (1992)
	16	Iino, et al, (1991) "Antiestrogen therapy for breast cancer: Current strategies and potential causes for therapeutic failure." <i>Cancer Treat. & Res.</i> 53:221-237.
	17	Kato, et al (1992) "A Far Upstream Estrogen Response Element of the Ovalbumin Gene Contains Several Half-Palindromic 5'-TGACC-3' Motifs Acting Synergistically." <i>Cell</i> , vol. 68, pp. 731-742.
	18	Kushner et al. (1990) "Construction of Cell Lines that Express High Levels of the Human Estrogen Receptor and Are Killed by Estrogens." <i>Molecular Endocrinology</i> 4(10):1465-1473.
	19	Kushner, et al. (1992) Abstract, <i>Cold Spring Harbor Symposium</i> , September 2-5.
	20	Kushner, et al. (1995) "Tamoxifen and related antiestrogens are agonists of a novel pathway of estrogen receptor action." Abstract No. D. <i>Journal of Neurochemistry</i> 64(Suppl. 1). Twenty-Sixth Meeting of the American Society for Neurochemistry, Santa Monica, CA. March 5-9.
	21	Kumar, et al. (1987) "Functional Domains of the Human Estrogen Receptor." <i>Cell</i> , vol. 51, pp. 941-951.
	22	Kumar and Chambon, (1988) "The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer." <i>Cell</i> , vol. 55, pp. 145-156.
	23	Leitman, et al. (1992) "The Core Promoter Region of the Tumor Necrosis Factor alpha-Gene Confers Phorbol Ester Responsiveness to Upstream Transcriptional Activators." <i>Molecular and Cellular Biology</i> , 12:1352-1356.
	24	Love, et al. (1991) "Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women." <i>Annals of Internal Med.</i> , 115:860-864.
	25	Love, et al. (1992) "Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer." <i>New England J. Med.</i> , 326(13):852-856.
	26	Merck Index (1989) "4281. Genistein." 11 th Edition, page 686.
		Merck Index (1989) "3653. Estradiol." 11 th Edition, page 583.
	28	Pons, et al. (1990) "A New Cellular Model of Response to Estrogens: A Bioluminescent Test to Characterize (Anti) Estrogen Molecules." <i>Biotechniques</i> , 9:450-459.

Examiner Signature	Date
<i>[Signature]</i>	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
MAY 2 0 2002
PACIFIC CENTER 160012900

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/729,478
	Filing Date	December 4, 2000
	First Named Inventor	Peter J. Kushner
	Group Art Unit	1646
	Examiner Name	E. Kemmerer
	Attorney Docket Number	407T-896330US
Date Submitted		

29	Sambrook, et al. (1989) <i>Molecular Cloning: A Laboratory Manual, Second Edition</i> . Cold Spring Harbor Laboratory Press, NY. pp. 16.57-16.58.
30	Soto, et al. (1992) "An 'In-Culture' Bioassay to Asses the Extrogenicity of Xenobiotics (E-Screen)." <i>Advances in Modern Environmental Toxicology</i> . Vol. 21.
31	Spatz, et al. (1992) "Responsiveness of the 5'-Flanking Region of the Brain Type Isozyme of Creatine Kinase to Estrogens and Antiestrogen." <i>J. Steroid Biochem. Molec. Biol.</i> 41(3-8): 711-714.
32	Sundstrom., et al (1990) "The Stimulation of Uterine Complement Component C3 Gene Expression by Antiestrogens." <i>Endocrinology</i> 126(3): 1449-1456.
33	Umayahara, et al (1994) "Estrogen Regulation of the Insulin-like Growth Factor I Gene Transcription Involves an AP-1 Enhancer." <i>Journal of Biological Chemistry</i> , 269(23):16433-16442.
34	Wakeling (1990) "Therapeutic Potential of Pure Antiestrogens in the Treatment of Breast Cancer." <i>J. Steroid Biochem. Molec. Biol.</i> 37(6):771-775.
35	Wakeling (1993) "The future of new pure antiestrogens in clinical breast cancer." <i>Breast Cancer Research and Treatment</i> . 25:1-9.
36	Webb, et al. (1992) "The Limits of the Cellular Capacity to Mediate an Estrogen Response." <i>Molecular Endocrinology</i> . 6(2):157-167.
37	Webb, et al. (1995) "Tamoxifen activation of the estrogen receptor AP-1 pathway: Potential origin for the cell-specific Estrogen-like effects of antiestrogens." <i>Molecular Endocrinology</i> 9(4):443-456.
38	Williard, et al. (1995) "Screening and characterization of estrogenic activity from a hydroxystilbene library." <i>Chemistry & Biology</i> , 2(1):45-51.
39	Wolff et al. (1993) "Blood Levels of Organochlorine Residues and Risk of Breast Cancer." <i>J. Natl. Cancer Inst.</i> 85:648-652.
40	Philips et al. (1993) "Estradiol increases and anti-estrogens antagonize the growth factor induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis", <i>J. Biol. Chem.</i> 268 (19) 14103-14108.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.